The first two authors contributed equally to this paper Systemic sclerosis (SSc) is characterized by excessive fibrosis throughout the body. There are two major subsets ofSSc, diffuse cutaneous Systemic sclerosis (dSSc) and limited cutaneous Systemic sclerosis (ISSc). Fibroblasts playa key role in SSc. The expression and function of the urokinase (uPA)-mediated plasminogen activation (PA) system, a well-characterized system of serine-proteases involved in several pathological processes, has been investigated in SSc fibroblasts. The expression of the components of the PA system, including uPA, its type-l and type-2 inhibitors (PAI-l and PAI-2) and its receptor (uPAR), was examined by Western blot in fibroblasts from patients affected by limited and diffuse forms of SSc. uPA and PAI-l secretion increased only in fibroblasts from ISSc lesions compared to normal fibroblasts. PAI-2 levels were decreased in fibroblasts from both SSc forms. Interestingly, fibroblasts from areas not adjacent to the lesions (not-affected) of the diffuse form showed reduced levels of PAI-l and increased uPAR expression. Adhesion experiments showed reduced adherence to VN of fibroblasts from ISSc lesions and from non-affected areas of the diffuse form, as compared to normal controls. These results suggest a role for uPA and PAI-l in the ISSc form, likely related to the activation of latent forms of cytokines and to the accumulation ofECM components, whereas a role for uPAR can be hypothesized in the evolvement of the diffuse form, based on its up-regulation in the non-affected areas.
activation of the immune system and microvascular injury (2) , but the real cause is unknown.
Several cytokines, including Transforming Growth Factor-beta (TGF-beta) and Interleukin 4 (IL-4) are overexpressed in SSc skin and could influence the activation state of fibroblasts (3) .
Fibroblasts isolated from SSc lesions and cultured in vitro are characterized by increased synthesis of collagen and other extracellular matrix proteins, in agreement with the progressive accumulation of collagen (types I and III), fibronectin and proteoglycans in the interstitium and in the intima of small arteries. Thus, fibroblasts play a key role in deregulated extracellular matrix deposition and may serve as an experimental model for studying the molecular and cellular mechanisms underlying SSc fibrosis (2) .
Urokinase (uPA) converts plasminogen into active plasmin, a broad-spectrum serine-protease that, in tum, promotes the degradation of the extracellular matrix (ECM) by degrading ECM components and by activating several metalloproteases (4) . Plasmin also induces release and activation of latent cytokines such as IL-l, IL-6 and TGF-beta (5) (6) . uPA activity is regulated by the specific type-l and type-2 inhibitors (PAI-l and PAI-2), PAI-l being the most efficient inhibitor. uPA binds a specific receptor (uPAR) that is anchored to the cell surface by a glycosphingolipid tail (7) . uPAR is a three domain glycoprotein that focuses and enhances uPA activity on the cell surface and is also able to transduce uPAdependent intracellular signaling, although it lacks transmembrane and cytosolic portions (8) . uPAR acts as a receptor for other extracellular molecules, such as vitronectin (VN) (9) , an ECM component, and the cleaved high molecular mass kininogen (HKa) lacking the vasodilator peptide bradykinin. However, an efficient binding to uPA and VN requires full length uPAR (10) (11) . uPA positively regulates VN binding to uPAR, likely by inducing the formation of uPAR dimers that exhibit a higher affinity for VN as compared to monomers (12) . uPAR also interacts laterally with cell surface molecules, such as integrins and chemotaxis tMLP receptors and regulates their activity (10) (11) . These molecules likely mediate uPAR capability to activate cell signalling pathways (8) .
The uPA-mediated plasminogen activation (PA) system is involved in several pathologic and physiologic processes including thrombolysis, inflammation, cell migration, tissue remodelling and vascularization (4) (5) (6) (7) (8) . Thus, we investigated its expression and possible function in cultured fibroblasts obtained from patients affected by limited and diffuse forms of SSc.
MATERIALS AND METHODS

Patients
Twelve female patients affected by scleroderma, aged from 35 to 55 years, observed in the day hospital of the Dept. of Clinical and Experimental Medicine of Federico II Medical School, Naples, between January and July 2008, were admitted to the study, after informed consent and Ethics Committee approval. Five patients were denoted dSSc (with anti-Scl 70 positivity), the other 7 ISSc (all positive for anti-centromere antibodies). Mean disease duration was about 8 years (range 4-27). Lung involvement was present in 3 dSSc subjects, esophagopathy in 4 dSSc and in all ISSc cases. None of them had been submitted to steroid or penicillamine treatment for at least one month before the study.
Dermal fibroblasts were obtained from both groups by skin punch-biopsy carried out on involved areas (A) and on apparently non-involved areas (NA). Control normal fibroblasts were obtained by skin punch biopsy from 10 healthy donors.
Reagents
Rabbit anti-uPAR (Product N°399R) and anti-uPA (Product N°389) polyclonal antibodies were purchased from American Diagnostica (Greenwich, CT, USA); anti-PAI-I (Clone MAI-12) and PAI-2 (Clone MAI-21) mouse monoclonal antibodies from Biopool (Umea, Sweden). Horseradish peroxidase-conjugated antirabbit and anti-mouse IgG and the protein colorimetric assay were from BIORAD (Richmond, CO, USA). The enhanced chemioluminescence (ECL) detection kit was from Amersham International (Amersham, England), polyvinylidene fluoride (PVDF) filters from Millipore (Windsor, MA, USA). The protease inhibitor cocktail was from SIGMA (St. Louis, Missouri, USA) and vitronectin from Beckton and Dickinson (NJ, USA). Dulbecco Modified Eagle Medium (DMEM), heat-inactivated Fetal Calf Serum (FCS) and antibiotics were from Life Technologies (Gaithersburg, MD, USA).
Cell cultures
Surgical fragments were mechanically dissociated under a light microscope and subjected to trypsinization for 30 minutes at 37°C. After phosphate buffered saline (PBS) washings, cells were plated and cultured in Dulbecco Modified Eagle Medium (DMEM) with the addition of 10% FCS and 100 mg/ml penicillin and streptomycin.
Western blot
Derma fibroblast culture media and Iysates were analyzed by Western blot with specific antibodies. Fibroblast conditioned medium was prepared by incubating Ix I0 6 cells, plated the day before in 60 mm dishes, in 2 ml of serum-free culture medium containing Img/ml BSA; after 3 days of culture, conditioned media were collected, centrifuged and analyzed. Fibroblast total proteins were obtained by lysing cells in 1% Triton X-IOO/PBS in the presence of protease inhibitors; the protein content was measured by a colorimetric assay. 100 ug of protein or 45 III of fibroblast conditioned medium were electrophoresed on a 10% SDS-PAGE under non-reducing conditions and transferred onto a PVDF membrane. The membrane was blocked with 5% non-fat dried milk and probed with I ug/ml of anti-uPAR and 5 Ilg/ ml ofanti-uPA, anti-PAl-lor anti-PAI-2 antibodies. Finally, washed filters were incubated with horseradish peroxidaseconjugated anti-rabbit or anti-mouse antibodies and detected by ECL for I minute. uPAR filters were reprobed with anti-actin antibodies, as a loading control.
Adhesion assay
96-well flat bottom microtiter plates were coated with 20 ug/ml vitronectin or I% heat-denatured BSA, as a negative control, and incubated overnight at 4°C. The plates were then blocked by I h incubation at roomtemperature with I% heat-denatured BSA in PBS. Cells from all the patients and all the controls were harvested by 10 mM EDTA in PBS, since the urokinase-receptor can be affected by trypsin treatment. Washed cells were plated in coated wells (I x I0 5 cells/well) and incubated I h at 37°, 5%CO z ' Attached cells were fixed with 3% paraformaldehyde, incubated with 2% methanol and stained with 0.5% crystal violet in 20% methanol. Stain was eluted by 0.1 M sodium citrate in 50% ethanol, pH 4.2 and the absorbance at 540 nm was measured by a spectrophotometer.
Statistical analysis
Student's t-test was used to evaluate significant variations in uPAR, uPA, PAI-I and PAI-2 levels and in cell adhesion (p:S0.05).
RESULTS
uPA, PAl-I and PAI-2 secretion by SScfibroblasts
Fibroblasts isolated from SSc lesions show an increased synthesis of collagen and other extracellular matrix proteins and likely contribute to the in vivo accumulation of collagen, fibronectin and proteoglycans occurring in SSc. However, also an altered balance in pericellular proteolysis may be involved in the observed extracellular matrix accumulation. Thus, we examined the secretion of the urokinase plasminogen activator (uPA) and its inhibitors by derma fibroblasts obtained from healthy donors and from patients affected by ISSc and dSSc. Derma fibroblasts (I x I0 6 ) from affected and non-affected areas (A and NA, respectively) of SSc patients and from healthy donors (N) were incubated in serum-free medium for 72 h at 37°C. The media from patients and normal subjects were analyzed in parallel by Western blot with anti-uPA, anti-PAI-I and anti-PAI-2 antibodies. Band intensities were then estimated by densitometric scanning and the means±SEM of the resulting values are summarized in Table I . All the analyzed samples showed the presence of uPA, PAI-I and PAI-2 (Figs. I, 2, 3, respectively). Fig. I shows that a significant increase in uPA secretion was observed only in fibroblasts obtained from ISSc lesions (lSSc-A) as compared both to their non-affected counterparts (lSSc-NA) (p: 0.007) and to normal fibroblasts (N) (p: 0.016). All ISSc fibroblasts showed an up-regulation of PAl-I secretion as compared to normal fibroblasts, however PAl-I levels were significantly increased only in fibroblasts from affected areas (lSSc-A) (p: 0.046). By contrast, PAl-I levels were reduced in fibroblasts from the diffuse form; but reduction was significant only in fibroblasts from non-affected areas (dSSc-NA) as compared to normal fibroblasts (N) (p: 0.0002). The differences between NA and A areas of the diffuse form were not significant (p: 0.125) (Fig. 2) .
PAI-2 levels were decreased in fibroblasts from all pathologic donors as compared to normal controls (p of ISSc-NA, ISSc-A, dSSc-NA, dSSc-A vs N: 0.0096,0.0061, 0.0045, 0.033, respectively); significant variations were not observed between affected and non-affected areas (Fig. 3) .
In conclusion, uPA and its type-I inhibitor are up-regulated in ISSc fibroblasts. By contrast, uPA levels remain unchanged in the diffuse form, where a significant PAl-I decrease is observed in non-affected areas. PAI-2 levels are significantly decreased in all fibroblasts from SSc patients.
uPAR expression in SSe fibroblasts
uPAR regulates cell surface-associated proteolysis by focusing uPA-dependent plasminogen activation on the cell membrane and is a central molecule in the uPA-mediated PA system. We then investigated the uPAR expression in derma fibroblasts obtained from patients affected by ISSc and dSSc. Derma fibroblasts from affected and non-affected. areas (A and NA, respectively) of SSc patients and from healthy donors (N) were analyzed in parallel by Western blot with an anti-uPAR polyclonal antibody. The analysis showed in all samples the presence of a 50 kDa band corresponding to full length uPAR ( Fig. 4, upper pane\) . uPAR levels were estimated by densitometric scanning and normalized to actin levels; the mean±SEM of the resulting values are presented in Fig. 4 (lower panel) and Table I. uPAR expression did not vary either in ISSc fibroblasts from affected and non-affected areas as compared to normal fibroblasts (p: 0.16 and 0.362, respectively), or in dSSc fibroblasts from affected areas (p: 1.05).
Interestingly, a significant increase in uPAR expression was observed in fibroblasts from nonaffected areas of the diffuse form as compared to their affected counterparts (p: 0.004) and to normal controls (p: 0.0002) .
SSe fibroblast adhesion to vitronectin
uPAR acts as a receptor for vitronectin (VN) , an extracellular matrix component, and uPA facilitates their interaction. We investigated whether uPA and/ or uPAR variations could influence SSc adherence to VN. Cell adhesion assays showed a significantly reduced adherence to VN of lSSc fibroblasts from affected and non-affected areas compared to healthy donors (p~0.006 and p:SO.OO 1, respectively). Reduced adhesion to VN was also observed in fibroblasts from non-affected areas of dSSc as compared to normal controls, unlike their affected counterparts (p:S0.002 and p:S0.075, respectively) ( Fig. 5) . Therefore, the observed differences in VN binding seem mostly related to integrin receptors .
Thus, fibroblast adhesion to VN seems unrelated to uPAR expression, since it decreases in lSSc fibroblasts, in which uPAR expression is similar to that of normal fibroblasts, and decreases also in fibroblasts from non-affected areas of the diffuse form, in which uPAR expression is significantly increased compared to control cells.
DISCUSSION
The plasminogen activation (PA), a wellcharacterized system of serine-proteases, represents a very efficient proteolytic machinery and its activation leads to dramatic degradation effects on the ECM, therefore its activity must be strictly regulated. The most efficient inhibitor ofplasminogen activators is the type-I inhibitor (PA]-I). The other specific PA inhibitor is the type-2 inhibitor (PAI-2). Its lower inhibitory efficiency, as compared to PAI-l and the intracellular detection of non-glycosylated, non-secreted forms suggested a role in the regulation of the activity of other enzymes; its involvement in apoptosis, independently of uPA inhibition, has been reported (13) . uPA binding to a specific cellular receptor (uPAR) represents another regulatory step of extracellular proteolysis, since it strongly enhances the proteolytic cascade ( 14) . Recent findings showed the involvement of uPA-mediated plasminogen activation system components in Sistemic Sclerosis (SSc). uPAR cleavage by metalloprotease-12 (MMP 12) could contribute to reduced angiogenic properties of microvascular endothelial cells (MVECs) from SSc patients, likely by inhibiting beta2 integrin-mediated connection of uPAR with the actin cytoskeleton (15) (16) (17) . Moreover, u-PA, uPAR and PA]-I levels in plasma of SSc patients were increased as compared to plasma from healthy controls and were modulated by intravenous alphacyclodestrine (Alprostadil) (l 8). Since fibroblasts seem to play a key role in disregulated extracellular matrix deposition, thus leading to fibrosis, a hallmark of SSc disease (1-2), we explored the expression of the PA system components in fibroblasts obtained from skin biopsies of patients affected by both SSc forms, the limited (ISSc) forms and the diffuse (dSSc) form. In fact, uPA activates a proteolytic cascade that can lead to the degradation of extracellular matrix components, including collagen, that is largely accumulated in SSc, probably protecting from fibrosis. Indeed, urokinase treatment in acute digital ischemia of progressive systemic sclerosis (19) systemic sclerosis (20) and in bleomycin-induced pulmonary fibrosis (21) exerted positive effects. In agreement with this observation, we found significant modifications in uPAsecretion in fibroblasts from the SSc form.
On the other hand, uPA can contribute to SSc by cleaving its own receptor (22) , thus impairing angiogenesis, as previously mentioned (15) (16) (17) . In addition, among the various substrates of uPAactivated plasmin , there are latent growth factors, including TGF-beta (5), one of the several cytokines that have been implicated in the development of fibrosis. TGF-beta stimulates collagen synthesis, and plasma levels of this cytokine are elevated in SSc patients (both lSSc and dSSc). Fibroblasts from skin of SSc patients express increased amounts of mRNA for TGF-beta and show increased levels ofTGF-beta. Furthermore, these fibroblasts are not as sensitive as normal fibroblasts to TGF-beta, suggesting that they are already stimulated maximally (1) . Recent findings suggest that alterations of the TGF-beta signaling in systemic sclerosis fibroblasts may facilitate increased collagen production in vivo even under conditions of low ligand availability (2) . Postnatal induction of TGF-beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features ofSSc (3). Thus, uPA may contribute to SSc progression by inducing plasmindependent release of TGF-beta and stimulating SSc fibroblasts by an autocrine loop.
However, together with uPA increase in the lSSc form, we also found a significant increase in its specific inhibitor, PAl-I. The observed PAI-l increase is in total agreement with previous reports. In fact, PAI-l levels are up-regulated in bleomycininduced murine SSc (23) , and fibrotic tissue accumulation within subcutaneously implanted polyvinyl alcohol sponges is significantly reduced in PAl-I -/-mice (24) . Moreover, PAl-I overexpression is a feature of keloid fibroblasts in which it could be one of the causes of collagen accumulation (25) . Taken together, these observations suggest that PAIl-dependent inhibition of uPA proteolytic activity may promote disregulated matrix deposition and fibrosis. In fact, increased levels of other protease inhibitors have been found in SSc patients, including serum tissue inhibitor of metalloproteinase I (TIMP-I); this may allow fibrosis progression because of a lack of collagenase activity (26) . Further evidence suggests that TIMP-I may behave as an autocrine growth factor in the fibrotic process of SSc (27) .
The simultaneous up-regulation of both uPA and its inhibitor is not unexpected, since has been observed in several cases, including renal fibrosis (28) .
We also studied the expression of uPAR, that focuses uPA activity on the cell membrane and accelerates plasmin generation. Indeed, uPAR importance in fibrosis has been demonstrated in uPAR -/-mice, in which uPAR deficiency, i.e. the absence of focused extracellular proteolysis, accelerates renal fibrosis in obstructive nephropathy (28) . We found that the expression of uPAR was unaltered in ISSc fibroblasts, thus suggesting that, in this form, uPA is involved probably by TGF-beta activation. On the contrary, we found a significant increase in uPAR expression, together with a significant down regulation of PAl-I, in dSSc fibroblasts from non-affected areas.
It seems therefore that, in the affected areas of ISSc, the balance between proteolysis and uPA inhibition is in favour of collagen deposition, since the strong increase of the uPA levels, not accompanied by a corresponding uPAR increase, is not sufficient to overcome the inhibition by the elevated levels of PAl-I. In the non-affected areas of ISSc, which do not present a strong increase in the PAl-I levels, the balance is in favour of protection from fibrosis.
In the dSSc, there is no increase of the uPA levels, which probably limits the lesions in ISSc form, and the balance is in favour of collagen deposition, even though PAl-I is not increased. In the non-affected areas of dSSc, protection from fibrosis is probably due to the strong increase of uPAR and the strong decrease of PAl-I.
In both forms of SSc, PAI-2 secretion seems significantly decreased. This observation is only in apparent contrast with previous results which indicate PAI-2 as a hallmark of SSc (29) . However, only the not-glycosylated intracellular PAI-2 was shown to be increased, thus suggesting a different role ofthis inhibitor, likely involved in the inhibition of unidentified intracellular proteases.
Finally, variations in SSc fibroblast adhesion to vitronectin (VN) seem to be independent on the expression of uPAR, a VN receptor. Indeed, cell adhesion to VN is reduced both in ISSc fibroblasts, which express uPAR to the same extent of normal fibroblasts, and in fibroblasts from the non-affected areas of the diffuse form, where uPAR expression is up-regulated. Thus, this aspect and its correlation with SSc needs further investigation.
In conclusion, we found that the examined components of the plasminogen activation system are related to SSc; their functions may involve TGF-beta-dependent fibroblast activation, mainly in the diffuse form, and inhibition of the physiologic collagen degradation in the ISSc form.
Furthermore, these results support the hypothesis, previously reported (30) , that dSSc and ISSc have different immunopathogenic mechanisms and that the lack of involvement of non-affected skin areas in sclerodermic patients is only apparent.
